EYPT EyePoint, Inc. - Common Stock
NASDAQ · Pharmaceuticals · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 5, 2026
$3.25
· % 处于52周区间
· 高于低点
· 至高点
$3.1052周低点
$19.0152周高点
市值 (MRQ)
$276M
P/E (TTM)
-0.9
EPS (TTM)
$-3.75
收入 (TTM)
$3M
EYPT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$3.25
市值 (MRQ)
$276M
P/E (TTM)
-0.9
EPS (TTM)
$-3.75
收入 (TTM)
$3M
ROE (TTM)
-148.7%
52周区间
$3–$19
EYPT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2020年12月9日 | 1-for-10 | 反向 |
| 2008年6月11日 | 1-for-4 | 反向 |
关于 EyePoint, Inc. - Common Stock 公司概况（来自维基百科）
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ). QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Pharmaceuticals
员工214
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$31M2017-06-30 → 2025-12-31
EPS$-3.172017-06-30 → 2025-12-31
自由现金流$-243M2019-12-31 → 2025-12-31
净利率-10998.7%2019-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | EYPT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -0.95年均值 ≈-5.8 | ≈-5.8 | · | · | |
| P/S (TTM) | 99.15年均值 ≈19.7 | ≈19.7 | 56.0 | 估值过高 | |
| 市净率 (MRQ) | 1.75年均值 ≈2.8 | ≈2.8 | 1.6 | 估值过高 | |
| 股价/自由现金流 (TTM) | -1.05年均值 ≈-145.0 | ≈-145.0 | · | · | |
| 市现率 (TTM) | -1.05年均值 ≈116.8 | ≈116.8 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 0.95年均值 ≈2.9 | ≈2.9 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | EYPT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -11369.3%5年均值 ≈-333.3% | ≈-333.3% | -754.4% | 弱 | |
| EBITDA Margin (息税折旧摊销前利润率) | -768.6%5年均值 ≈-331.8% | ≈-331.8% | -390.9% | 弱 | |
| Pretax Margin (税前利润率) | -738.5%5年均值 ≈-319.9% | ≈-319.9% | 36.2% | 弱 | |
| 净利润率 (TTM) | -10998.7%5年均值 ≈-320.2% | ≈-320.2% | 9.1% | 弱 | |
| ROA (TTM) | -115.9%5年均值 ≈-39.7% | ≈-39.7% | -6.9% | 弱 | |
| ROE (TTM) | -148.7%5年均值 ≈-61.0% | ≈-61.0% | -7.6% | 弱 | |
| ROIC | -79.6%5年均值 ≈-49.9% | ≈-49.9% | -20.1% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | EYPT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 4.55年均值 ≈7.4 | ≈7.4 | 11.1 | 低流动性 | |
| Quick Ratio (速动比率) | 8.35年均值 ≈6.8 | ≈6.8 | 4.5 | 持平 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | EYPT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | -27.5%5年均值 ≈-0.59% | ≈-0.59% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | -8.8%5年均值 ≈2.2% | ≈2.2% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | -1.8% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | EYPT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.15年均值 ≈0.2 | ≈0.2 | 0.1 | 顶尖 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$146.6K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-7.8%
下次报告
十一月 03, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 4, 2026 | $-1.09 | $-0.97 | -12.3% |
| 2026年3月31日 | $-0.99 | $-0.82 | -20.1% | |
| 2025年12月31日 | $-0.81 | $-0.76 | -6.2% | |
| 2025年9月30日 | $-0.85 | $-0.80 | -6.2% | |
| 2025年6月30日 | $-0.85 | $-0.81 | -4.6% | |
| 2025年3月31日 | $-0.65 | $-0.67 | 2.8% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31M | $43M | $46M | $41M | $37M | $34M | $20M | $5M | $8M | $2M | $27M | |
| R&D Expense | $221M | $133M | $65M | $50M | $28M | $17M | $15M | $19M | $15M | $14M | $12M | |
| SG&A Expense | $52M | $52M | $40M | $35M | $26M | $21M | $18M | $15M | $11M | $9M | $8M | |
| Operating Expenses | $275M | $189M | $121M | $141M | $92M | $72M | $68M | $44M | $26M | $23M | $20M | |
| Operating Income | $-243M | $-146M | $-75M | $-100M | $-55M | $-37M | $-48M | $-39M | $-19M | $-22M | $6M | |
| Interest Expense | · | · | $1M | $3M | $5M | $7M | $6M | $2M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | $19.0K | |
| Other Non-op | $12M | $15M | $7M | $2M | $292.0K | $58.0K | $1M | $420.0K | $91.0K | $72.0K | $22.0K | |
| Pretax Income | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | · | $-18M | $-22M | $6M | |
| Income Tax | $279.0K | $90.0K | $83.0K | · | $0 | $0 | $0 | · | $0 | $-155.0K | $96.0K | |
| Net Income | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | $-86M | $-18M | $-22M | $6M | |
| EPS (Basic) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | · | · | · | $-0.52 | $-0.68 | $0.22 | |
| EPS (Diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | · | · | · | $-0.52 | $-0.68 | $0.21 | |
| Shares (Basic) | 73,251 | 56,298 | 38,904 | 37,317,000 | 28,758,000 | · | · | · | 35,343,765 | 31,623,473 | 29,378,250 | |
| Shares (Diluted) | 73,251 | 56,298 | 38,904 | 37,317,000 | 28,758,000 | · | · | · | 35,343,765 | 31,623,473 | 30,584,140 | |
| EBITDA | $-241M | $-146M | $-75M | $-100M | $-55M | · | $-48M | · | · | $-22M | $6M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $100M | $281M | $96M | $179M | $45M | $22M | $45M | $17M | $15M | $19M | |
| Short-term Investments | $204M | $271M | $50M | $49M | $33M | $0 | $0 | $0 | $0 | $14M | $9M | |
| Inventory | $2M | $2M | $4M | $3M | $4M | $5M | $2M | $279.0K | · | · | · | |
| Prepaid Expense | $20M | $9M | $9M | $10M | $4M | $3M | $6M | $1M | $591.0K | $483.0K | $681.0K | |
| Other Current Assets | $2M | $1M | $1M | $782.0K | $517.0K | · | · | · | · | · | · | |
| Current Assets | $329M | $383M | $345M | $173M | $238M | $63M | $42M | $48M | $18M | $30M | $30M | |
| PP&E (Net) | $9M | $8M | $5M | $1M | $476.0K | $630.0K | $357.0K | $288.0K | $313.0K | $290.0K | $338.0K | |
| PP&E (Gross) | $15M | $12M | $8M | $3M | $2M | $2M | $1M | $983.0K | $799.0K | $2M | $2M | |
| Accum. Depreciation | $6M | $4M | $3M | $2M | $1M | $1M | $839.0K | $695.0K | $486.0K | $2M | $2M | |
| Intangibles | · | · | · | $0 | $23M | $25M | $28M | $30M | $364.0K | $1M | $2M | |
| Other Non-current Assets | $6M | $6M | $0 | · | · | · | · | · | · | · | · | |
| Total Assets | $364M | $418M | $355M | $180M | $263M | $92M | $73M | $78M | $19M | $32M | $32M | |
| Accounts Payable | $10M | $12M | $7M | $6M | $7M | $5M | $4M | $3M | $1M | $1M | $744.0K | |
| Accrued Liabilities | $24M | $18M | $18M | $16M | $14M | $8M | $7M | $4M | $4M | $4M | $3M | |
| Short-term Debt | · | · | $0 | $10M | $0 | · | · | · | · | · | · | |
| Current Liabilities | $37M | $49M | $63M | $35M | $24M | $15M | $12M | $21M | $5M | $5M | $3M | |
| Capital Leases | $21M | $22M | $5M | $6M | $2M | $2M | $3M | $0 | · | · | · | |
| Other Non-current Liabilities | $87.0K | $205.0K | $0 | $600.0K | $2M | $2M | $3M | $1M | $51.0K | · | · | |
| Total Liabilities | $58M | $82M | $89M | $84M | $79M | $73M | $65M | $41M | $5M | $11M | $9M | |
| Long-term Debt | · | · | · | $30M | · | · | · | · | · | · | · | |
| Total Debt | · | · | $0 | $40M | $37M | · | $47M | · | · | · | · | |
| Common Stock | $83.0K | $68.0K | $49.0K | $34.0K | $34.0K | $18.0K | $11.0K | $95.0K | $39.0K | $34.0K | $29.0K | |
| Retained Earnings | $-1.10B | $-873M | $-742M | $-671M | $-569M | $-511M | $-465M | $-408M | $-311M | $-292M | $-271M | |
| AOCI | $961.0K | $1M | $864.0K | $786.0K | $841.0K | $841.0K | $840.0K | $839.0K | $833.0K | $852.0K | $945.0K | |
| Stockholders' Equity | $306M | $337M | $266M | $96M | $184M | $19M | $8M | $38M | $13M | $21M | $23M | |
| Liabilities + Equity | $364M | $418M | $355M | $180M | $263M | $92M | $73M | $78M | $19M | $32M | $32M | |
| Shares Outstanding | 82,826,416 | 68,266,005 | 49,043,074 | 34,082,934 | 33,905,826 | 18,139,981 | 10,941,659 | 95,372,236 | 39,356,999 | 34,172,919 | 29,412,365 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $464.0K | · | · | · | · | · | · | · | · | |
| Stock-based Comp | $28M | $37M | $12M | $14M | $7M | $6M | $5M | · | $2M | $2M | $2M | |
| Deferred Tax | $279.0K | $90.0K | $83.0K | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | $0 | $2M | $2M | $2M | $2M | $981.0K | $724.0K | $756.0K | $770.0K | |
| Restructuring | · | · | · | · | · | $590.0K | · | · | $472.0K | · | · | |
| Other Non-cash | $-39M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-240M | $-126M | $2M | $-65M | $-50M | $-14M | $-57M | · | $-20M | $-16M | $10M | |
| CapEx | $3M | $4M | $3M | $2M | $156.0K | $362.0K | $213.0K | · | $147.0K | $113.0K | $161.0K | |
| Investing Cash Flow | $69M | $-219M | $-3M | $-17M | $-33M | $-362.0K | $-213.0K | · | $14M | $-4M | · | |
| Debt Issued | · | · | $0 | $30M | $0 | · | $50M | · | $0 | $0 | · | |
| Net Debt Issued | · | $0 | $-30M | $-8M | $0 | · | $30M | · | · | · | · | |
| Stock Issued | $173M | $163M | $226M | $0 | · | $50M | $23M | · | $8M | $16M | $0 | |
| Net Stock Activity | $173M | $163M | $226M | · | · | · | $23M | · | · | $16M | · | |
| Financing Cash Flow | $174M | $164M | $187M | $-690.0K | $217M | $37M | $34M | · | $9M | $17M | · | |
| Net Change in Cash | $2M | $-182M | $186M | $-83M | $134M | $23M | $-23M | · | $2M | $-4M | $4M | |
| Taxes Paid | $200.0K | $100.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-243M | $-130M | $-2M | $-67M | $-50M | · | $-57M | · | · | $-16M | $10M | |
| Levered FCF | · | · | $-3M | $-70M | $-56M | · | $-63M | · | · | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | · | -235.0% | · | · | -1344.1% | 24.2% | |
| Net Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | · | -278.9% | · | · | -1330.1% | 23.9% | |
| Pretax Margin | -738.5% | -302.2% | -153.7% | -247.0% | -158.1% | · | -278.9% | · | · | -1339.6% | 24.2% | |
| EBITDA Margin | -768.6% | -337.1% | -163.1% | -240.6% | -149.6% | · | -235.0% | · | · | -1344.1% | 24.2% | |
| ROA | -59.3% | -33.8% | -26.4% | -46.1% | -32.9% | · | -75.1% | · | · | -67.3% | 23.1% | |
| ROE | -84.0% | -47.1% | -43.6% | -87.9% | -42.2% | · | -468.1% | · | · | -90.8% | 24.8% | |
| ROIC | -79.6% | -43.4% | -28.2% | -73.2% | -25.0% | · | -86.2% | · | · | -103.5% | 27.1% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.9 | 7.8 | 5.5 | 5.0 | 10.0 | · | 3.6 | · | · | 5.9 | 8.9 | |
| Quick Ratio | 8.3 | 7.6 | 5.2 | 4.2 | 8.9 | · | 1.9 | · | · | 5.7 | 8.5 | |
| Debt / Equity | · | · | 0.0 | 0.4 | 0.2 | · | 5.7 | · | · | · | · | |
| LT Debt / Equity | · | · | · | 0.3 | 0.2 | · | 5.7 | · | · | · | · | |
| Interest Coverage | · | · | -60.2 | -31.2 | -10.1 | · | -7.7 | · | · | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | · | 0.3 | · | · | 0.1 | 1.0 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.70 | $4.93 | $5.43 | $2.83 | $5.44 | · | $0.08 | · | · | $0.61 | $0.79 | |
| Revenue / Share | $428.27 | $768.64 | $1.18 | $1.11 | · | · | · | · | · | $0.05 | $0.87 | |
| Cash Flow / Share | $-3277.91 | $-2242.10 | $0.05 | $-1.74 | · | · | · | · | · | $-0.52 | $0.34 | |
| Cash / Share | $1.23 | $1.46 | $5.74 | $2.81 | $5.27 | · | $0.20 | · | · | $0.45 | $0.65 | |
| EPS (TTM) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 | $-0.67 | $-0.67 | · | $-0.52 | $-0.68 | $0.21 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -27.5% | -6.0% | 11.1% | 12.1% | 7.3% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.8% | 5.4% | 10.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -1.8% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $31M | $43M | $46M | $41M | $37M | $34M | $20M | · | $8M | $2M | $27M | |
| Net Income TTM | $-232M | $-131M | $-71M | $-102M | $-58M | $-45M | $-57M | · | $-18M | $-22M | $6M | |
| Market Cap | $1.51B | $509M | $1.13B | $119M | $415M | · | $1.70B | · | · | $967M | $1.11B | |
| Enterprise Value | · | · | $802M | $15M | $240M | · | $1.72B | · | · | · | · | |
| P/E | -5.8 | -3.2 | -12.7 | -1.3 | -6.0 | -9.8 | -23.1 | · | -32.9 | -41.6 | 179.5 | |
| P/S | 48.2 | 11.8 | 24.6 | 2.9 | 11.2 | · | 83.3 | · | · | 597.0 | 41.7 | |
| P/B | 4.9 | 1.5 | 4.3 | 1.2 | 2.3 | · | 203.6 | · | · | 46.3 | 47.5 | |
| P / Tangible Book | 4.9 | 1.5 | 4.3 | 1.2 | 2.6 | · | · | · | · | · | · | |
| P / Cash Flow | -6.3 | -4.0 | 604.5 | -1.8 | -8.3 | · | -29.9 | · | · | -59.3 | 107.7 | |
| P / FCF | -6.2 | -3.9 | -704.8 | -1.8 | -8.3 | · | -29.8 | · | · | -58.9 | 109.4 | |
| EV / EBITDA | · | · | -10.7 | -0.1 | -4.3 | · | -36.0 | · | · | · | · | |
| EV / FCF | · | · | -499.0 | -0.2 | -4.8 | · | -30.2 | · | · | · | · | |
| EV / Revenue | · | · | 17.4 | 0.4 | 6.5 | · | 84.5 | · | · | · | · | |
| Earnings Yield | -17.3% | -31.1% | -7.9% | -78.3% | -16.6% | -10.2% | -4.3% | · | -3.0% | -2.4% | 0.56% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $507.0K | $696.0K | $619.0K | $966.0K | $5M | $24M | $12M | $11M | $9M | $12M | $14M | $15M | $9M | $8M | $11M | $10M | |
| Cost of Revenue | · | · | · | · | · | · | · | $736.0K | $1M | $759.0K | · | $1M | $2M | $640.0K | · | · | |
| R&D Expense | $84M | $72M | $59M | $48M | $55M | $59M | $43M | $30M | $30M | $30M | $18M | $17M | $16M | $14M | $16M | $11M | |
| SG&A Expense | $14M | $15M | $11M | $14M | $12M | $14M | $13M | $13M | $13M | $14M | $11M | $11M | $9M | $9M | $8M | $9M | |
| Operating Expenses | $98M | $88M | $71M | $63M | $68M | $73M | $57M | $43M | $44M | $45M | $30M | $30M | $32M | $29M | $54M | $28M | |
| Operating Income | $-97M | $-87M | $-70M | $-62M | $-62M | $-49M | $-45M | $-33M | $-35M | $-33M | $-16M | $-14M | $-23M | $-22M | $-44M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $0 | $0 | · | $0 | $435.0K | $812.0K | $781.0K | $662.0K | |
| Other Non-op | $3M | $2M | $3M | $2M | $3M | $4M | $4M | $3M | $4M | $4M | $2M | $2M | $2M | $1M | $1M | $640.0K | |
| Pretax Income | $-94M | · | $-67M | $-60M | $-59M | · | $-41M | $-29M | $-31M | · | · | · | · | · | · | · | |
| Income Tax | $0 | $-50.0K | $186.0K | $0 | $93.0K | $0 | $90.0K | $0 | $0 | · | · | · | · | · | · | · | |
| Net Income | $-94M | $-85M | $-68M | $-60M | $-59M | $-45M | $-41M | $-29M | $-31M | $-29M | $-14M | $-13M | $-23M | $-21M | $-43M | $-18M | |
| EPS (Basic) | $-1.09 | $-0.99 | $-0.82 | $-0.85 | $-0.85 | $-0.65 | $-0.65 | $-0.54 | $-0.58 | $-0.55 | $-0.32 | $-0.33 | $-0.61 | $-0.56 | $-1.17 | $-0.49 | |
| EPS (Diluted) | $-1.09 | $-0.99 | $-0.82 | $-0.85 | $-0.85 | $-0.65 | $-0.65 | $-0.54 | $-0.58 | $-0.55 | $-0.32 | $-0.33 | $-0.61 | $-0.56 | $-1.17 | $-0.49 | |
| Shares (Basic) | 86,543 | 85,999 | · | 70,168 | 69,926 | 69,767 | · | 54,449 | 53,206 | 52,913,000 | · | 38,341,000 | 37,576,000 | 37,486 | · | 37,338,000 | |
| Shares (Diluted) | 86,543 | 85,999 | · | 70,168 | 69,926 | 69,767 | · | 54,449 | 53,206 | 52,913,000 | · | 38,341,000 | 37,576,000 | 37,486 | · | 37,338,000 | |
| EBITDA | $-97M | $-87M | · | $-62M | $-62M | $-49M | · | $-33M | $-35M | $-33M | · | $-14M | $-23M | $-22M | · | $-18M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110M | $78M | $102M | $75M | $71M | $85M | $100M | $80M | $91M | $271M | $281M | $133M | $140M | $106M | $96M | $75M | |
| Short-term Investments | $70M | $145M | $204M | $129M | $185M | $233M | $271M | $174M | $189M | $28M | $50M | $3M | $3M | $17M | $49M | $82M | |
| Inventory | $2M | $1M | $2M | $2M | $3M | $2M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $4M | $3M | $4M | |
| Prepaid Expense | $6M | $25M | $20M | $9M | $6M | $6M | $9M | $12M | $10M | $11M | $9M | $9M | $9M | $9M | $10M | $10M | |
| Other Current Assets | $987.0K | $1M | $2M | $899.0K | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $549.0K | $0 | $0 | $782.0K | · | |
| Current Assets | $189M | $250M | $329M | $216M | $265M | $327M | $383M | $269M | $295M | $318M | $345M | $150M | $167M | $146M | $173M | $192M | |
| PP&E (Net) | $10M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $5M | $4M | $3M | $3M | $1M | $1M | |
| PP&E (Gross) | · | · | $15M | · | · | · | $12M | · | · | · | $8M | · | · | · | $3M | · | |
| Accum. Depreciation | · | · | $6M | · | · | · | $4M | · | · | · | $3M | · | · | · | $2M | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | |
| Other Non-current Assets | $9M | $9M | $6M | $6M | $6M | $6M | $6M | $2M | · | · | $0 | · | · | · | · | · | |
| Total Assets | $228M | $288M | $364M | $252M | $301M | $363M | $418M | $301M | $324M | $329M | $355M | $160M | $176M | $155M | $180M | $220M | |
| Accounts Payable | $17M | $19M | $10M | $10M | $20M | $16M | $12M | $7M | $14M | $7M | $7M | $10M | $11M | $9M | $6M | $6M | |
| Accrued Liabilities | $22M | $16M | $24M | $18M | $11M | $18M | $18M | $14M | $13M | $16M | $18M | $13M | $15M | $10M | $16M | $16M | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $5M | $10M | $10M | |
| Current Liabilities | $42M | $37M | $37M | $30M | $33M | $42M | $49M | $49M | $62M | $63M | $63M | $64M | $69M | $27M | $35M | $34M | |
| Capital Leases | $20M | $20M | $21M | $21M | $22M | $22M | $22M | $22M | $22M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | |
| Other Non-current Liabilities | $23.0K | $55.0K | $87.0K | $118.0K | $148.0K | $177.0K | $205.0K | $233.0K | · | · | $0 | $0 | $0 | $600.0K | $600.0K | $600.0K | |
| Total Liabilities | $62M | $58M | $58M | $52M | $55M | $64M | $82M | $82M | $96M | $79M | $89M | $101M | $118M | $76M | $84M | $84M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | · | $30M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $35M | · | $40M | |
| Common Stock | $85.0K | $83.0K | $83.0K | $70.0K | $69.0K | $69.0K | $68.0K | $53.0K | $52.0K | $50.0K | $49.0K | $35.0K | $34.0K | $34.0K | $34.0K | $34.0K | |
| Retained Earnings | $-1.28B | $-1.19B | $-1.10B | $-1.04B | $-978M | $-918M | $-873M | $-832M | $-802M | $-771M | $-742M | $-728M | $-715M | $-693M | $-671M | $-628M | |
| AOCI | $793.0K | $802.0K | $961.0K | $919.0K | $832.0K | $923.0K | $1M | $1M | $792.0K | $836.0K | $864.0K | $841.0K | $842.0K | $843.0K | $786.0K | $653.0K | |
| Stockholders' Equity | $166M | $230M | $306M | $200M | $246M | $298M | $337M | $219M | $228M | $250M | $266M | $59M | $57M | $78M | $96M | $136M | |
| Liabilities + Equity | $228M | $288M | $364M | $252M | $301M | $363M | $418M | $301M | $324M | $329M | $355M | $160M | $176M | $155M | $180M | $220M | |
| Shares Outstanding | 84,981,843 | 83,453,001 | 82,826,416 | 69,569,813 | 68,889,649 | 68,811,357 | 68,266,005 | 53,524,364 | 52,160,305 | 49,885,701 | 49,043,074 | 35,309,432 | 34,306,118 | 34,301,926 | 34,082,934 | 34,072,155 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $690.0K | $636.0K | $698.0K | $576.0K | $538.0K | $497.0K | $467.0K | $408.0K | $362.0K | $303.0K | $112.0K | · | · | · | · | · | |
| Stock-based Comp | $10M | $12M | $7M | $6M | $7M | $8M | $8M | $7M | $9M | $13M | $4M | $4M | $2M | $3M | $3M | $3M | |
| Deferred Tax | · | · | $369.0K | $0 | · | · | $90.0K | $0 | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $205.0K | $615.0K | |
| Other Non-cash | · | $-8M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-62M | $-81M | $-65M | $-59M | $-63M | $-53M | $-36M | $-39M | $-20M | $-31M | $-23M | $-15M | $57M | $-17M | $-13M | $-13M | |
| CapEx | $1M | $997.0K | $986.0K | $798.0K | $1M | $276.0K | $384.0K | $2M | $900.0K | $1M | $883.0K | $2M | $396.0K | $484.0K | $585.0K | $1M | |
| Investing Cash Flow | $75M | $59M | $-75M | $55M | $48M | $40M | $-96M | $16M | $-160M | $21M | $-47M | $-2M | $13M | $32M | $33M | $6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | · | · | $167M | $7M | · | · | $152M | · | · | · | $216M | · | · | · | $0 | · | |
| Financing Cash Flow | $20M | $-3M | $167M | $7M | $238.0K | $-951.0K | $152M | $12M | $329.0K | $115.0K | $218M | $10M | $-37M | $-5M | $-58.0K | $92.0K | |
| Net Change in Cash | $33M | $-24M | $27M | $3M | $-14M | $-15M | $20M | $-11M | $-180M | $-10M | $148M | $-7M | $34M | $10M | $20M | $-7M | |
| Free Cash Flow | · | $-82M | · | · | · | $-53M | · | · | · | $-32M | · | · | · | $-17M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -19207.1% | -12532.5% | · | -6420.8% | -1166.8% | -199.7% | · | -311.2% | -364.5% | -285.2% | · | -94.7% | -250.0% | -280.5% | · | -183.8% | |
| Net Margin | -18633.1% | -12188.5% | · | -6183.4% | -1114.3% | -184.8% | · | -279.0% | -325.3% | -250.6% | · | -83.0% | -251.7% | -275.5% | · | -184.0% | |
| Pretax Margin | -18633.1% | · | · | -6183.4% | -1112.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -19207.1% | -12441.1% | · | -6420.8% | -1166.8% | -199.7% | · | -311.2% | -364.5% | -285.2% | · | -94.7% | -250.0% | -280.5% | · | -183.8% | |
| ROA | -35.7% | -26.1% | · | -21.6% | -19.0% | -13.1% | · | -12.7% | -12.3% | -12.1% | · | -6.6% | -11.2% | -10.6% | · | -9.5% | |
| ROE | -45.8% | -32.1% | · | -28.5% | -25.1% | -16.5% | · | -21.2% | -21.6% | -17.8% | · | -12.9% | -22.0% | -17.3% | · | -16.1% | |
| ROIC | -58.5% | · | · | -31.0% | -25.3% | · | · | · | · | · | · | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.7 | · | 7.2 | 8.0 | 7.8 | · | 5.5 | 4.7 | 5.1 | · | 2.4 | 2.4 | 5.4 | · | 5.6 | |
| Quick Ratio | 4.3 | 5.9 | · | 6.8 | 7.7 | 7.6 | · | 5.2 | 4.5 | 4.8 | · | 2.1 | 2.1 | 4.5 | · | 4.6 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.4 | · | 0.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.4 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | · | -52.3 | -26.5 | · | -27.8 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.2 | 0.4 | 0.2 | · | · | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.96 | $2.76 | · | $2.88 | $3.57 | $4.34 | · | $4.09 | $4.38 | $5.01 | · | $1.66 | $1.67 | $2.29 | · | $4.00 | |
| Revenue / Share | $5.86 | $8.09 | · | $13.77 | $76.27 | $0.35 | · | $0.19 | $0.18 | $220.82 | · | $0.40 | $0.24 | $0.20 | · | $0.27 | |
| Cash Flow / Share | · | $-936.63 | · | · | · | $-0.76 | · | · | · | $-589.10 | · | · | · | $-0.45 | · | · | |
| Cash / Share | $1.30 | $0.93 | · | $1.07 | $1.03 | $1.24 | · | $1.49 | $1.74 | $5.43 | · | $3.77 | $4.07 | $3.08 | · | $2.21 | |
| EPS (TTM) | $-3.75 | $-3.51 | · | $-3.00 | $-2.69 | $-2.42 | · | $-1.99 | $-1.78 | $-1.81 | · | $-2.67 | $-2.83 | $-2.74 | · | $-2.18 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3M | $8M | · | $42M | $52M | $56M | · | $46M | $50M | $50M | · | $43M | $37M | $40M | · | $42M | |
| Net Income TTM | $-307M | $-272M | · | $-206M | $-175M | $-147M | · | $-104M | $-87M | $-79M | · | $-100M | $-106M | $-102M | · | $-78M | |
| Market Cap | $1.22B | $1.08B | · | $991M | $648M | $373M | · | $428M | $454M | $1.03B | · | $282M | $298M | $101M | · | $270M | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | $146M | $156M | $13M | · | $152M | |
| P/E | -3.8 | -3.7 | · | -4.7 | -3.5 | -2.2 | · | -4.0 | -4.9 | -11.4 | · | -3.0 | -3.1 | -1.1 | · | -3.6 | |
| P/S | 435.9 | 141.3 | · | 23.4 | 12.5 | 6.7 | · | 9.4 | 9.0 | 20.6 | · | 6.6 | 8.0 | 2.5 | · | 6.4 | |
| P/B | 7.3 | 4.7 | · | 4.9 | 2.6 | 1.2 | · | 2.0 | 2.0 | 4.1 | · | 4.8 | 5.2 | 1.3 | · | 2.0 | |
| P / Tangible Book | 7.3 | 4.7 | · | 4.9 | 2.6 | 1.2 | · | 2.0 | 2.0 | 4.1 | · | 4.8 | 5.2 | 1.3 | · | 2.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -7.0 | · | · | · | -33.1 | · | · | · | -6.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | 3.4 | 4.2 | 0.3 | · | 3.6 | |
| Earnings Yield | -26.2% | -27.2% | · | -21.1% | -28.6% | -44.6% | · | -24.9% | -20.5% | -8.8% | · | -33.4% | -32.5% | -93.2% | · | -27.6% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $31M | $43M | $46M | $41M | $37M |
| 营业利润率 % | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% |
| 净收入 | $-232M | $-131M | $-71M | $-102M | $-58M |
| 稀释后每股收益 (EPS) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | · | · | 0.0 | 0.4 | 0.2 |
| 流动比率 | 8.9 | 7.8 | 5.5 | 5.0 | 10.0 |
| 速动比率 | 8.3 | 7.6 | 5.2 | 4.2 | 8.9 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-243M | $-130M | $-2M | $-67M | $-50M |
机构持有人 (13F) 214 家申报者 · $1.5B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
214
持有价值
$1.5B
新仓位
29
已退出持仓
21
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 29 (-33 与上一季度对比) | 21 (-2 与上一季度对比) | 66 (-10 与上一季度对比) | 60 (+22 与上一季度对比) | +2.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $118638163 | 8296375 | 8.06% | 股份 |
| BlackRock, Inc. | $106723718 | 7463197 | 7.25% | 股份 |
| Cormorant Asset Management, LP | $100100000 | 7000000 | 6.80% | 股份 |
| VANGUARD GROUP INC | $88100480 | 4822139 | 5.99% | 股份 |
| FEDERATED HERMES, INC. | $81239044 | 5681052 | 5.52% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $69037426 | 4827792 | 4.69% | 股份 |
| FRANKLIN RESOURCES INC | $68741215 | 4807078 | 4.67% | 股份 |
| Commodore Capital LP | $65780000 | 4600000 | 4.47% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $51912604 | 3630252 | 3.53% | 股份 |
| JANUS HENDERSON GROUP PLC | $46419056 | 3601168 | 3.15% | 股份 |
| Paradigm Biocapital Advisors LP | $41332677 | 2890397 | 2.81% | 股份 |
| STATE STREET CORP | $33712894 | 2357545 | 2.29% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $29497382 | 2062390 | 2.00% | 股份 |
| Aberdeen Group plc | $28725869 | 2008802 | 1.95% | 股份 |
| PERCEPTIVE ADVISORS LLC | $28600000 | 2000000 | 1.94% | 卖出期权 |
| CITADEL ADVISORS LLC | $28279823 | 1977610 | 1.92% | 股份 |
| Balyasny Asset Management L.P. | $25916719 | 1812358 | 1.76% | 股份 |
| Parkman Healthcare Partners LLC | $18420731 | 1288163 | 1.25% | 股份 |
| EVENTIDE ASSET MANAGEMENT, LLC | $17811837 | 1245583 | 1.21% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $16890345 | 1181143 | 1.15% | 股份 |
| Essex Woodlands Management, Inc. | $15513455 | 1084857 | 1.05% | 股份 |
| ORBIMED ADVISORS LLC | $15288802 | 1069147 | 1.04% | 股份 |
| 5AM Venture Management, LLC | $15015000 | 1050000 | 1.02% | 股份 |
| Rosalind Advisors, Inc. | $14131689 | 988230 | 0.96% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13885500 | 971014 | 0.94% | 股份 |
| AMERIPRISE FINANCIAL INC | $12132298 | 848410 | 0.82% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $12035896 | 841746 | 0.82% | 股份 |
| HSBC HOLDINGS PLC | $11918407 | 833455 | 0.81% | 股份 |
| Candriam S.C.A. | $11254258 | 787769 | 0.76% | 股份 |
| Artia Global Partners LP | $10969501 | 767098 | 0.75% | 股份 |
| Blue Owl Capital Holdings LP | $10905094 | 762594 | 0.74% | 股份 |
| NORTHERN TRUST CORP | $10309113 | 720917 | 0.70% | 股份 |
| Patient Square Capital LP | $10296000 | 720000 | 0.70% | 股份 |
| Principia Wealth Advisory, LLC | $9293530 | 649944 | 0.63% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9260866 | 647613 | 0.63% | 股份 |
| Sio Capital Management, LLC | $8910759 | 623130 | 0.61% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $7996789 | 559216 | 0.54% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7899320 | 552400 | 0.54% | 买入期权 |
| Alyeska Investment Group, L.P. | $7284463 | 509403 | 0.50% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $7151330 | 500093 | 0.49% | 股份 |
| GOLDMAN SACHS GROUP INC | $6650744 | 465087 | 0.45% | 股份 |
| Simplify Asset Management Inc. | $5720629 | 400044 | 0.39% | 股份 |
| Ikarian Capital, LLC | $5296720 | 370400 | 0.36% | 买入期权 |
| Ikarian Capital, LLC | $5296720 | 370400 | 0.36% | 卖出期权 |
| Ghisallo Capital Management LLC | $5005000 | 350000 | 0.34% | 股份 |
| STEMPOINT CAPITAL LP | $4840135 | 338471 | 0.33% | 股份 |
| MORGAN STANLEY | $4815240 | 336730 | 0.33% | 股份 |
| E Fund Management Co., Ltd. | $4730068 | 330774 | 0.32% | 股份 |
| Jump Financial, LLC | $4586825 | 320757 | 0.31% | 股份 |
| Bleichroeder LP | $4526165 | 316515 | 0.31% | 股份 |
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| EW Healthcare Partners L.P., EW Healthcare Partners-A L.P., Essex Woodlands Fund IX-GP, L.P., Essex Woodlands IX, LLC, Martin P. Sutter, R. Scott Barry, Ronald Eastman, Petri Vainio, Steve Wiggins ×4 申报 | 2023年12月8日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2023年8月30日 | · | 初始申报 | · | SEC |
| Ocumension Therapeutics | 2021年1月22日 | · | 初始申报 | · | SEC |
| IRS Identification Nos. of above persons (entities only) Pfizer Inc. ×2 申报 | 2017年5月26日 | · | 初始申报 | · | SEC |
| Pfizer Inc. | 2007年7月17日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 34 位内幕人士 · 14 位高管 · 22 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jay S. Duker | President and CEO | 2026年7月10日 M | 9594 | 1 | 0 | $19725 |
| Paul Ashton | President & CEO | 2016年3月18日 M | 450741 | 0 | 0 | $0 |
| George Elston | Chief Financial Officer | 2026年8月20日 G | 64953 | 0 | 0 | $0 |
| David Price | CFO | 2019年6月25日 A | · | 0 | 0 | $0 |
| Michael Soja | VP Finance, CFO & Treasurer | 2008年9月10日 A | · | 0 | 0 | $0 |
| Ramiro Ribeiro | Chief Medical Officer | 2026年6月30日 M | 0 | 0 | 7 | $-948955 |
| Dario A. Paggiarino | Chief Medical Officer | 2024年3月30日 M | 67080 | 0 | 0 | $0 |
| David Scott Jones | SVP & Chief Commercial Officer | 2024年2月9日 M | 44916 | 0 | 0 | $0 |
| Michael Craig Pine | Chief Corp Dev.&Strat. Officer | 2024年1月6日 M | 13662 | 0 | 0 | $0 |
| Leonard S Ross | VP Finance and Chief Accounting Officer | 2019年6月27日 M | 90044 | 0 | 0 | $0 |
| Leonard M Blum | Executive VP and General Manager, US | 2018年5月14日 A | · | 0 | 0 | $0 |
| Debora Jorn | EVP, Corp. & Comm'l Dev. | 2017年6月27日 A | · | 0 | 0 | $0 |
| Lori Freedman | VP Corporate Affairs, General Counsel and Secretary | 2016年7月21日 A | 96423 | 0 | 0 | $0 |
| Aaron Finlay | Secretary | 2007年10月18日 A | · | 0 | 0 | $0 |
| Karen L. Zaderej | 董事 | 2026年8月18日 P | 49100 | 1 | 0 | $52258 |
| Nancy Lurker | 董事 | 2026年1月6日 M | 294346 | 0 | 3 | $-150988 |
| Reginald J. Sanders | 董事 | 2026年1月2日 A | · | 0 | 0 | $0 |
| Stuart Duty | 董事 | 2026年1月2日 A | · | 0 | 0 | $0 |
| John B. Landis | 董事 | 2026年1月2日 A | 21400 | 0 | 0 | $0 |
| Wendy F Dicicco | 董事 | 2026年1月2日 A | 9967 | 0 | 0 | $0 |
| ANDO GORAN | 董事 | 2026年1月2日 A | 13150 | 0 | 0 | $0 |
| Fred Hassan | 董事 | 2026年1月2日 A | · | 0 | 0 | $0 |
| David R Guyer | 董事 | 2024年7月12日 M | 1850 | 0 | 0 | $0 |
| Anthony P Adamis | 董事 | 2024年6月23日 M | 4000 | 0 | 0 | $0 |
| Ye Liu | 董事 | 2024年1月11日 S | 100221 | 0 | 0 | $0 |
| OcuMension Therapeutics | 董事 | 2024年1月11日 S | 100221 | 0 | 0 | $0 |
| Douglas Evan Godshall | 董事 | 2021年6月22日 A | 8016 | 0 | 0 | $0 |
| Kristine Peterson | 董事 | 2020年2月28日 A | 6667 | 0 | 0 | $0 |
| David J Mazzo | 董事 | 2019年10月9日 M | 200083 | 0 | 0 | $0 |
| Michael W Rogers | 董事 | 2019年6月25日 A | 119167 | 0 | 0 | $0 |
| James J Barry | 董事 | 2018年5月7日 M | 12500 | 0 | 0 | $0 |
| SAVAS PETER G | 董事 | 2015年12月3日 A | · | 0 | 0 | $0 |
| Paul Hopper | 董事 | 2013年12月18日 A | 10000 | 0 | 0 | $0 |
| Katherine Woodthorpe | 董事 | 2007年11月27日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 30 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1.13% | 19051 NS | 2026年7月31日 | N-PORT |
| BBC · ETFis Series Trust I | 0.63% | 23853 NS | 2026年7月31日 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.38% | 26636 SH | 2026年10月2日 | 每日 |
| IWC · iShares Trust | 0.08% | 263363 SH | 2026年9月11日 | 每日 |
| IHE · iShares Trust | 0.08% | 290098 SH | 2026年9月11日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | 0.06% | 86797 SH | 2026年8月19日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.05% | 69310 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.03% | 36951 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.03% | 445218 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.02% | 5967 SH | 2026年10月2日 | 每日 |
| IWO · iShares Trust | 0.02% | 607108 SH | 2026年9月11日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.02% | 207955 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 35128 NS | 2026年7月31日 | N-PORT |
| IWM · iShares Trust | 0.01% | 1984162 SH | 2026年9月11日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 901417 SH | 2026年8月19日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 11210 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.01% | 213549 SH | 2026年8月19日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 60232 SH | 2026年10月2日 | 每日 |
| WSML · iShares Trust | 0.00% | 4573 SH | 2026年9月11日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.00% | 5922 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 48608 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 10667 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 16256 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 111657 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 22216 SH | 2026年9月3日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2643860 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 6035 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 121398 SH | 2026年9月11日 | 每日 |
| ISCB · iShares Trust | · | 3155 SH | 2026年9月11日 | 每日 |
| ISCV · iShares Trust | · | 15627 SH | 2026年9月11日 | 每日 |
EYPT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 19 位分析师
买入
中位数目标
$20.00
+515.4%
6 31.6%
强烈买入
7 36.8%
买入
6 31.6%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
11 位分析师 · 2026-09-30平均目标 $25.91 +697.2%
← 低于所有目标
当前价格 $3.25
最低$4.00
平均值$25.91
最高$68.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 5, 2026 申报